Key result
Meloxicam (up to 30 mg daily) significantly inhibited TxB2 production (peak 77% inhibition) but did not significantly increase bleeding time or inhibit platelet aggregation compared with placebo.
Why the study?
Does meloxicam affect bleeding time, TxA2 formation, and platelet aggregation compared to placebo and indomethacin in healthy adults?
RCT (n=79)
Double-blind
Does meloxicam affect bleeding time, TxA2 formation, and platelet aggregation compared to placebo and indomethacin in healthy adults?
Meloxicam, even at supratherapeutic doses, does not significantly impair in vivo platelet function or bleeding time in healthy adults, unlike nonselective NSAIDs.
No takes yet. Share an insight, caveat, or question.
Supports safer NSAID selection in bleeding-prone patients; confirms meloxicam spares platelet aggregation and bleeding time despite TxB2 inhibition.
Rinder et al. (2002) conducted an RCT in Healthy (n=79). Meloxicam vs. Placebo and extended-release indomethacin (75 mg once daily) was evaluated on Bleeding time, TxA2 formation (serum TxB2), and platelet aggregation. Meloxicam (up to 30 mg daily) significantly inhibited TxB2 production (peak 77% inhibition) but did not significantly increase bleeding time or inhibit platelet aggregation compared with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: